Location History:
- Munich, DE (2022)
- Sankt Wolfgang, DE (2023)
Company Filing History:
Years Active: 2022-2025
Title: The Innovations of Manon Weis: Pioneering T Cell Receptor Research in Munich
Introduction
Manon Weis is a notable inventor based in Munich, Germany, recognized for her significant contributions to the field of immunotherapy. With a total of four patents to her name, Weis is making strides in the development of innovative solutions for cancer treatment through her research and inventions.
Latest Patents
Weis's latest patents showcase her expertise in T cell receptor (TCR) technology. One of her notable inventions is focused on MAGEA1-specific T cell receptors, which are isolated receptors targeting MAGEA1-derived peptides. This patent includes a polypeptide comprising a functional portion of the TCR and outlines a multivalent TCR complex, nucleic acid encoding the TCR, cells expressing the TCR, and pharmaceutical compositions containing these TCRs. This TCR is particularly emphasized for its potential use as a medicament in cancer treatment.
Another significant patent involves an isolated T cell receptor specific for NY-ESO-1/LAGE-1. Similar to her MAGEA1 patent, this invention encompasses the multivalent TCR complex, a nucleic acid encoding the TCR, and its applications as a cancer treatment. These patents reflect Weis's dedication to developing advanced therapies aimed at improving patient outcomes in oncology.
Career Highlights
Manon Weis is currently employed at Medigene Immunotherapies GmbH, where she continues to work on impactful immunotherapy projects. Her role involves collaboration with various teams to enhance the development of TCR-based therapies. Weis's contributions have positioned her as a key figure in the rapidly evolving sector of cancer immunotherapy.
Collaborations
While at Medigene Immunotherapies GmbH, Weis works alongside accomplished colleagues such as Carina Wehner and Silke Raffegerst. These collaborations enable a synergistic approach to research and development, fostering innovation within the company and advancing the fight against cancer through tailored immunotherapy strategies.
Conclusion
In summary, Manon Weis has established herself as a prominent inventor in the field of immunotherapy, with a focus on T cell receptors for cancer treatment. Her latest patented innovations reflect a determined effort to improve therapeutic strategies and provide hope for many patients. Weis's work at Medigene Immunotherapies GmbH and her collaborations with talented coworkers underscore the importance of teamwork in pioneering medical advancements.